Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Inclusion Criteria: * Stage II, III,or IV lung or pancreatic cancer * Fair, poor, or very poor appetite * Cancer associated anorexia/cachexia * Weight loss perceived to be associated with diminished appetite * Eastern Cooperative Oncology Group Performance score of 0, 1, 2 * Life expectancy \>3 months * Alert and mentally competent * Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year * Screening laboratory values must not be clinically significant (some exceptions per protocol) Exclusion Criteria: * Brain, or head and neck metastases that may interfere with food consumption * AIDS-related wasting * Radiation therapy to the head and neck, abdomen, or pelvis within past 6 weeks, or anticipated during course of the study such that the result may interfere with food consumption * Conditions that interfere with oral intake, or ability to swallow * Absence of a normally functioning gut * Mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome * Intractable or frequent vomiting that regularly interfere with eating * Clinically significant diarrhea * History of recurrent thromboembolic events, a thromboembolic event in past 3 months, or long-term anticoagulation treatment for thromboembolism * Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism * Poorly controlled hypertension, or congestive heart failure * Pregnant/lactating females * Use within past 30 days of an appetite stimulant * Use within past week, or planned use during the study of parenteral nutrition or tube feedings * Chronic use of steroids within past 3 months (intermittent short-term use allowed) * Current use of or not willing to abstain from using illicit substances * Allergy, hypersensitivity, or contraindication to megestrol acetate